Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Asep Medical Holdings Inc C.ASEP

Alternate Symbol(s):  SEPSF

ASEP Medical Holdings Inc. is a Canada-based company, which is in the business of acquiring research and development assets, technologies and/or businesses in the area of life sciences and medical diagnostics. The Company’s consolidates three development-stage companies, including Sepset Biosciences Inc., ABT Innovations Inc., and SafeCoat Medical Inc. It provides medical devices with an anti-microbial, antifouling coating through its SafeCoat Medical Inc. The Company provides diagnostic kits for predicting the onset of severe Sepsis and organ failure through its Sepset Biosciences Inc. The Company also offers peptide technology through its ABT Innovations Inc. and covers a range of therapeutic applications, including bacterial biofilm infections, anti-inflammatories, anti-infective immune-modulators and vaccine adjuvants. SafeCoat Medical Inc.'s technology incorporates self-assembling biocompatible polymers combined with conjugated antimicrobial peptides.


CSE:ASEP - Post by User

Post by waves1on Jan 19, 2022 3:43pm
70 Views
Post# 34334431

ASEP's diagnostic and therapeutic applications

ASEP's diagnostic and therapeutic applications
$ASEP.c is trading at quite an attractive valuation right now given it's located in a market full of unmet needs.
 
As ASEP offers a rapid way to identify sepsis as well as treat it, they are positioned to win a meaningful share in the market. Their diagnostic application has a clear and easy path to generate revenue, which is notable given its commercialization is expected in mid-2022. Plus, ASEP's therapeutic product is expected to be fast-tracked to clinical trials within the next year as well.

https://asepmedical.com/investors/ 
<< Previous
Bullboard Posts
Next >>